Every one of those 1 sits in a single category, pharma. Qelbree is most often covered alongside NovoCure Limited, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Qelbree, all published on February 26, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Qelbree
Every one of those 1 sits in a single category, pharma. Qelbree is most often covered alongside NovoCure Limited, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Qelbree, all published on February 26, 2026. Each carries 7 original sources on average.
Stories tracked
1
Sources per story
7
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Qelbree. Shared-story counts are live from our verified record — not editorial picks.
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.